Le Lézard
Classified in: Health, Science and technology
Subjects: TRI, SCZ

NetNoggin® releases exploratory analysis "Alzheimer's Recent Drug Failures"


FREDERICK, Md., Oct. 2, 2019 /PRNewswire/ -- An exploratory study, conducted by NetNoggin®, revealed that among those impacted by Alzheimer's, hope of finding a cure is deflating due to recent Alzheimer's clinical trial failures in the past few years:

Inspired by the consumer. (PRNewsfoto/NetNoggin)

In fact, the last successful Alzheimer's drug approval was in 2014 for NAMZARIC. Manufacturers acknowledge current drugs for Alzheimer's only treat symptoms as the disease continues to progress.

In response to news regarding failed clinical trials, caregivers are posting responses claiming this news makes them "depressed' and "pessimistic".  Yet, researchers and foundations remain hopeful despite the failures. For example, George Vradenburg, the head of USAgainstAlzheimers, posted on Twitter, "Let's keep failing ... until we succeed ... [help] us all to remain hopeful in the fight against #Alz."

Results from NetNoggin's analysis also show growing concern that the amyloid hypothesis may be the wrong target and other mechanisms should be considered. The community suggests the following next steps:

Visit https://netnoggin.net/exploratory-analysis to request the full exploratory analysis.

About NetNoggin®
NetNoggin®, a subsidiary of Conger Consulting, LLC, is a premier market research agency that specializes in pharmaceutical marketing. NetNoggin® utilizes netnography to analyze and provide context to Big Data. By leveraging 30+ years of experience, their proprietary process derives strategic consulting insights from Big Data to inform Foundational Marketing Tools (FMTs), strategies, and tactics. NetNoggin® has expertise in market research; commercial, market, and clinical development; and communications to provide reliable research, presentations, and workshops.

NetNoggin® Media Relations
If you would like more information on this topic, please contact Megan Newcomer.
E-mail: megan.newcomer@netnoggin.net

SOURCE NetNoggin


These press releases may also interest you

at 15:05
Battelle and The Ohio State University Wexner Medical Center have jointly developed a new rapid, sensitive diagnostic test for COVID-19. The Ohio State Wexner Medical Center will administer the new test under its existing FDA certification permits....

at 15:01
Along with the ever-growing healthcare industry, W Medical Strategy Group (WMSG) has provided consulting services to more than 100 clients, accumulating more than 3 billion dollars in transaction values for the past 6 years. Healthcare companies...

at 15:00
MedImpact, a pharmacy benefit manager based in San Diego, California, has partnered with Bellevue, Washington based Translational Software & Genetics (TSI), to provide a full service pharmacogenetic solution for MedImpact plan members. MedImpact, can...

at 15:00
As health care facilities rise to meet the challenge of the COVID-19 pandemic, these health care facilities are suffering significant daily loss of revenue as they are mandated to reallocate resources to dealing with the outbreak...at the expense of...

at 15:00
Kinetic Vet, an animal health company, today announced the launch of its latest product, ArmourGuard® RTU, an EPA-approved spray-on antimicrobial solution. As a first-of-its-kind technology within the animal health industry, ArmourGuard RTU is the...

at 14:45
The Ragon Institute of MGH, MIT and Harvard today announced it has received a gift from Nancy Zimmerman to help fund development of an early response coronavirus (COVID-19) diagnostic that would support medical and other front-line professionals and...



News published on 2 october 2019 at 15:51 and distributed by: